July 2009-"It is very important to understand that our initial drug formulation is ready now, which often costs major pharmaceutical companies millions of dollars to reach this stage. Our initial pre-IND work will establish non-clinical product safety (safety pharmacology, pharmacokinetics, and toxicology) under FDA guidelines. We are also identifying and establishing appropriate GMP compliant testing and manufacturing facilities. If the assumptions we make about pre-existing information are accurate, our costs in time and money to get to the pre-IND meeting with the *FDA will be much less because our initial drug formulation is ready now. (SEE THE COMMENT FROM YESTERDAY'S PR AT THE BOTTOM OF THIS POST).
We look forward to working with the FDA and to following their recommendations with the steps that are required to ultimately produce our first FDA approved pharmaceutical product," stated, Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D.
And in another article in July 09-Cannabis Science to Apply to the FDA to Utilize Their Fast Track Procedures to Help Speed the Approval of Its Cannabinoid Medicines in Treatment of H1N1 Swine Flu as AP Report Predicts Swine Flu Could Hit up to 40 Percent in the USA
October of 09-Dr. Melamede concluded by saying, "We think that it is our duty to continue to emphasize that cannabis can play a very important role in treating respiratory diseases such as multiple influenza strains and asthma. There is an ever-increasing demand for our cannabis-based drugs, and this demand is growing exponentially throughout the United States and the rest of the world because it works. Modern science supports the public demand for cannabis-based FDA approved drug products that reduce the impact of critical life altering illnesses. The public need for our products drives our efforts to rapidly move our drugs through all available regulatory channels. We believe this enormous public demand on a global scale is a major key to our success and we are very excited to be positioned to provide solutions."
And another in Oct-09-CNN Reports President Obama Declares National Emergency To Deal With The "Rapid Increase In Illness" From The H1N1 Influenza Virus; Cannabis Science Continues Progress On Its Research To Show Cannabis Can Reduce Risk of Death from "Swine Flu"
February 9, 2010
Cannabis Science Inc. (CBIS) Announces Progress in Bringing the First Cannabis Based Medicine to Market Company Moving Towards Contracts and Licensing Agreements for Research and Development of New Medicines
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), a pharmaceutical cannabis company in the US, is pleased to announce it is finalizing agreements with suppliers, manufactures, and research institutions that it expects will close within days and weeks to come. Once these agreements are closed they will be announced along with details on how CBIS will bring its first Cannabis based pharmaceutical products to market.
February 25th 2010-COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), a pharmaceutical cannabis company, is pleased to report to their shareholders that the choice of our initial cannabis-based pharmaceutical for FDA clinical trials has been made. The Company has reported several possible drugs for FDA clinical trials. Based on extensive studies, the Company has decided to contract with a group based in Colorado to handle the Company’s FDA filings. Appropriate announcements will be made when the contracts are finalized.
March 1, 2010
Cannabis Science Officially Begins Its First Pre-IND FDA Application Process For Post Traumatic Stress Disorder (PTSD)
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), a pharmaceutical cannabis company in the US, is pleased to announce that it now has the results of its survey of more than 1,300 individuals with PTSD, including a large cohort of veterans. The survey was conducted by Cannabis Science Advisory Board member Dr. Mitch Earleywine PhD. of the State University of New York (Albany).
March 10, 2010
The Company has reported several prospective drugs for FDA clinical trials. Based on extensive studies and this survey, the Company now has the substantiated data to for its first application for a PTSD drug for FDA clinical trials. The Company will now sign a pre-negotiated contract with a group of FDA specialists based in Colorado to handle the Company’s first FDA filings.
President Obama's Deputy Drug Czar Tom McClellan Comments in USA TODAY Article; Endorses Non-Smoked Medical Marijuana Delivery Systems Identical to the First Product Cannabis Science is Developing for FDA Clinical Trials for PTSD Targeting Our Veterans, Active Duty Troops, and Others Suffering from Disasters World-Wide
COLORADO SPRINGS, Colo., -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US pharmaceutical cannabis company, notes that comments by President Obama's Deputy Director of the White House Office of National Drug Control Policy, Tom McClellan, in yesterday's USA TODAY pinpoints the need for non-smoked medical cannabis products similar to those currently being developed for FDA clinical trials by Cannabis Science.
*Yesterday-The company realizes that in order to bring cannabis-based medications and remedies to the mainstream market, extensive research is necessary.
SO, IT'S NOT READY NOW AS STATED BACK IN 2009?
News 
Market Data 
Discover 
AI
